Evidence map›Paper›PMID 41062855›Full record

ArticleAnnals of hematology2025

Early-life clinical and hematological profiles: a comparative study of children with and without sickle cell disease in the first three years of life.

Siana Nkya, Isihaka Mahawi, Rehema Shungu, Collin Nzunda, Frida Kaywanga, David Solomon, Theogloria Kerrety, Emmanuel Josephat, Heavenlight Christopher, Doreen Ngowi and 13 more

Abstract readComparative Study
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Siana NkyaDepartment of Biochemistry and Molecular Biology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Isihaka MahawiDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. isihakamahawi96@gmail.com.
Rehema ShunguDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Collin NzundaDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Frida KaywangaDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
David SolomonDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Theogloria KerretyDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Emmanuel JosephatDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Heavenlight ChristopherDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Doreen NgowiDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Julieth JohansenDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Florence UrioDepartment of Biochemistry and Molecular Biology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Josephine MgayaSickle Cell Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Upendo MasamuSickle Cell Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Clara ChambaDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Raphael SangedaSickle Cell Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Fadya HashimPediatric department, Mnazi Mmoja Hospital, Zanzibar, Tanzania.
Emmanuela AmbroiseBugando Medical Centre, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Lulu ChirandeSickle Cell Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Agnes JonathanSickle Cell Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Emmanuel BalandyaSickle Cell Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Solomon Ofori AcquahUniversity of Ghana, Accra, Ghana.
Julie MakaniDepartment of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

Funding

Sickle Pan-African Research Consortium (SPARCO)- TanzaniaU01HL156853 · NHLBI · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI BALANDYA, EMMANUEL · 2021 to 2025
$1.5M
The role of HbF decline and its determinants on Sickle Cell Disease expression in the first three years of life.K43TW011167 · FIC · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI NKYA, SIANA WATOKY · 2019 to 2023
$534k
FIC NIH HHS K43 TW011167FIC NIH HHS K43TW011167NHLBI NIH HHS U01 HL156853
6 · The paper itself

Abstract

Sickle cell disease (SCD) has been associated with significant morbidity and mortality, particularly in early childhood. Understanding the hematological and clinical outcomes during the early years of life is crucial for guiding interventions to improve care for affected populations. This study investigates the relationship between fetal hemoglobin (HbF) levels, hematological profiles, and clinical outcomes in children with SCD, from birth to three years of age. By comparing children with and without SCD, the study aimed to identify trends in disease progression and highlight the need for early screening and intervention. This longitudinal study recruited and followed children aged 0-3 years. Clinical complaints and hematological parameters were recorded at each visit. Statistical analyses explored associations between HbF levels, hematological parameters, and clinical outcomes in children with SCD. 414 children were recruited, 35.5% with SCD and 64.5% without SCD. Children with SCD experienced a higher frequency of clinical complaints. The hospital admission rate was higher among children with SCD (19.6%) compared to those without (1.7%) (p < 0.007), with severe anemia being the leading cause of admission (56.3%). At birth, children with SCD had higher HbF levels (72.87%) that declined over time. The rate of decline correlated with an increased frequency of clinical events in children with SCD. Additionally, children with SCD had lower red cell indices, and higher reticulocyte count as well as white blood cell count. The results emphasize the need for early intervention and continuous monitoring to manage the disease effectively. Further research is recommended to explore the impact of different interventions on improving the quality of life and survival rates in children with SCD.

Indexed as

Anemia, Sickle CellFetal HemoglobinChild, PreschoolFemaleHumansInfantInfant, NewbornLongitudinal StudiesMaleFetal HemoglobinClinical profileFetal hemoglobinHematological profileSickle cell disease

Identifiers

PMID41062855
PMCPMC12619737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.